Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature
Authors:
Open Access
- 30 October 2023
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 16 (1) , 1245-1252
Abstract
The advent of immune checkpoint inhibition opened new perspectives for patients with recurrent or metastasized renal cell carcinoma. In case of recurrent disease, surgical resection remains the most promising therapeutic option. Surgical resection is associated with improved overall survival and demonstrated curative potential given complete resection of metastases can be performed. This report presents the case of a patient with local recurrence of dedifferentiated sarcomatoid renal cell carcinoma approximately 1 year after initial open lumbar nephrectomy. After initial evaluation, surgical removal was deemed infeasible and an induction therapy with pembrolizumab and lenvatinib was initiated. After 3 months, corresponding to 5 cycles of pembrolizumab, the tumor showed a partial response on imaging control and was successfully resected en bloc. Histopathological examination of the specimen revealed no evidence of viable neoplastic cells. This is the first report describing a complete pathological response of a locally recurrent dedifferentiated sarcomatoid renal cell carcinoma after treatment with pembrolizumab and lenvatinib. Overall, the combination therapy was well tolerated with a maximum Common Terminology Criteria for Adverse Events Level of Two. These findings underline the potential of multimodal therapeutic strategies for recurrent renal cell carcinoma, such as induction therapies to downstage initially nonresectable masses, and highlight the need for prospective studies to allow for evidence-based treatment plans.Keywords
This publication has 15 references indexed in Scilit:
- Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohortInternational Urology and Nephrology, 2021
- Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic ReviewFuture Oncology, 2021
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell CarcinomaNew England Journal of Medicine, 2021
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trialJournal for ImmunoTherapy of Cancer, 2020
- Active surveillance of small renal massesInsights into Imaging, 2020
- Epidemiology of Renal Cell CarcinomaWorld Journal of Oncology, 2020
- Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2019
- Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database AnalysisEuropean Urology Focus, 2019
- Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomesBJU International, 2016
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 2016